Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hNNMT-897-LNA(18)
- Development stage
- Preclinical
- Lead developer
- Osaka University
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
hNNMT-897-LNA(18) is an investigational 2',4'-bridged nucleic acid (BNA)/locked nucleic acid (LNA)-modified gapmer phosphorothioate antisense oligonucleotide (ASO) developed by researchers at Osaka University. It is designed to specifically target and suppress the expression of nicotinamide N-methyltransferase (NNMT), an enzyme that is highly expressed in cancer-associated fibroblasts (CAFs) and various tumor tissues, where it correlates with poor prognosis. By inhibiting NNMT, the ASO aims to disrupt metabolic pathways that support tumor growth and the pro-tumorigenic environment created by CAFs. To enhance delivery and specificity to the tumor microenvironment, a version of this ASO has been conjugated with FAPI-04, a ligand that binds to fibroblast activation protein (FAP), allowing for targeted uptake by CAFs. Preclinical studies in xenograft models have demonstrated antitumor effects in pancreatic cancer and non-small-cell lung carcinoma.
- Other names
- NNMT antisense oligonucleotideFAPI-04-conjugated hNNMT-897-LNA(18)
02
Targets
NNMT (Nicotinamide N-methyltransferase)
Beyond the preview
Go deeper on hNNMT-897-LNA(18).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hNNMT-897-LNA(18).